Abstract | BACKGROUND: A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed. OBJECTIVE: METHODS: Three hundred forty-eight patients with plaque psoriasis were enrolled and 275 patients completed a multicenter, investigator-masked, randomized, parallel-group clinical trial. RESULTS: CONCLUSION:
|
Authors | M Lebwohl, E Ast, J P Callen, S I Cullen, S R Hong, C L Kulp-Shorten, N J Lowe, T J Phillips, T Rosen, D I Wolf, J M Quell, J Sefton, J C Lue, J R Gibson, R A Chandraratna |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 38
Issue 5 Pt 1
Pg. 705-11
(May 1998)
ISSN: 0190-9622 [Print] United States |
PMID | 9591815
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents
- Dermatologic Agents
- Gels
- Glucocorticoids
- Nicotinic Acids
- Prodrugs
- Fluocinonide
- tazarotene
|
Topics |
- Administration, Cutaneous
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Analysis of Variance
- Anti-Inflammatory Agents
(administration & dosage, therapeutic use)
- Child
- Dermatologic Agents
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Erythema
(drug therapy, pathology)
- Female
- Fluocinonide
(administration & dosage, therapeutic use)
- Follow-Up Studies
- Gels
- Glucocorticoids
- Humans
- Life Tables
- Male
- Middle Aged
- Nicotinic Acids
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Prodrugs
(administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
- Psoriasis
(drug therapy, pathology)
- Safety
- Single-Blind Method
- Skin
(pathology)
- Treatment Outcome
|